Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
87 hedge funds and large institutions have $280M invested in Kindred Biosciences, Inc. in 2021 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 21 increasing their positions, 22 reducing their positions, and 31 closing their positions.
389% more call options, than puts
Call options by funds: $4.06M | Put options by funds: $830K
79% more capital invested
Capital invested by funds: $156M → $280M (+$124M)
4% more funds holding
Funds holding: 84 → 87 (+3)
10% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 31
5% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$20M |
| 2 |
Millennium Management
New York
|
+$15.9M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
+$10.5M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$4.2M |
| 5 |
GF
Gabelli Funds
Rye,
New York
|
+$4.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13M |
| 2 |
BlackRock
New York
|
-$11M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
-$5.76M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.18M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.6M |
KIN Hedge Fund Activity: Q2 2021 in Review
87 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2021, worth a combined $280M — up 79% from $156M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new KIN positions and 31 closed out — a net gain of 3 holders — while 21 added to existing stakes and 22 trimmed.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $20M. The largest seller was Point72 Asset Management, cutting an estimated $13M.
- 87 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2021, up from 84 in Q1 2021.
- Funds reported $280M of Kindred Biosciences, Inc. stock for Q2 2021, up 79% quarter-over-quarter.
- 34 funds opened new Kindred Biosciences, Inc. positions in Q2 2021 and 31 closed out, a net change of +3 holders.
- The largest Kindred Biosciences, Inc. buyer in Q2 2021 was Magnetar Financial, an estimated $20M added.
- The largest Kindred Biosciences, Inc. seller in Q2 2021 was Point72 Asset Management, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2021.